Balanced news tone
News Sentiment
INSM sentiment intelligence
Insmed Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-6.3% over one week, +13.1% over four weeks, trend inactive, and materially above fair value.
Is Insmed (INSM) Undervalued After Positive TPIP Data Backed A Phase 3 Push?
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- PR Newswire
Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy
- Tone
- Positive 95/100
- Event
- Earnings
- Published
- 22 Jun 2026 07:00
- Source
- Seeking Alpha
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise?
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 22 Jun 2026 07:00
- Source
- Market source
Insmed (INSM) Remains a Strong Buy Despite Recent Stock Decline
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- GuruFocus
Is Insmed (INSM) The Best Healthcare Stock to Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Market source
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- Insmed Incorporated Investor Relations
A Look At Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Market source
Assessing Insmed (INSM) Valuation After Recent Share Price Pullback And Strong Multi Year Returns
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 19 May 2026 07:00
- Source
- Market source
Insmed Shelf Registration Raises Questions On Funding Flexibility And Valuation
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 May 2026 07:00
- Source
- simplywall.st
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Insmed stock (US4576693075): Truist cuts price target to $185 on competitive risks
- Tone
- Negative 18/100
- Event
- Analyst action
- Published
- 14 May 2026 07:00
- Source
- ad-hoc-news.de
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Insmed Incorporated (NASDAQ:INSM) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Insmed (INSM) Q1 2026 Revenue Surge Tests Profitability Narrative
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 May 2026 07:00
- Source
- simplywall.st
Here's What Analysts Are Forecasting For Insmed Incorporated (NASDAQ:INSM) After Its First-Quarter Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 May 2026 07:00
- Source
- Market source
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 07:00
- Source
- Market source
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Insmed Incorporated Investor Relations
Insmed pairs new lung-disease data with U.S. diagnosis grant
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Stock Titan
Is It Time To Reassess Insmed (INSM) After The Recent Share Price Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- simplywall.st
Insmed executives line up two healthcare investor conference talks in May
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Apr 2026 07:00
- Source
- Stock Titan
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 10 Apr 2026 07:00
- Source
- 24/7 Wall St.
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Mar 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Insmed CEO reveals Japan patient population exceeds US market for lung disease
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- 24/7 Wall St.
Trade Alert: Independent Director Of Insmed Leo Lee Has Sold Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Nov 2025 08:00
- Source
- simplywall.st
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Nov 2025 08:00
- Source
- Market source